Health
-
Should Aging Be Treated As A Disease? And How One Company Might Be Shifting The Paradigm To Reverse It
Originally Published on Benzinga Technical advancements in stem cell therapies have reportedly shifted the outlook of regenerative medicine, and some scientists are getting increasingly excited. Cardiologist Dr. Joshua Hare is one of those scientists, and he’s both the co-founder and chief scientific officer of Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing cellular therapies for aging-related and life-threatening conditions. He’s also credited with helping to pioneer the use of stem cells as medicine for the human heart and regularly explores a future where regenerative medicine can prolong human life. The global regenerative medicine market is estimated to reach $6.49 billion in 2027, up 9.3% from $3.05 billion in 2019. …
-
MedTech Company BioSig Technologies Deploys Disruptive Technology To Improve Arrhythmia Care
This article was previously published to Benzinga. Arrhythmia is a heart condition that causes it to beat either too fast, or irregularly. It’s triggered by abnormal electrical activity and affects the heart’s rhythm, leading it to beat out of sync with the rest of the body. Not every patient experiences arrhythmia in the same way, so it’s sometimes necessary for doctors to provide each patient with a personalized approach to treatment and recovery. Lifestyle choices and comorbidities, medication, stress and environmental factors can cause the heart to beat out of sync. The world is experiencing an uptick in arrhythmia cases linked to the after effects of COVID-19. Atrial fibrillation (AFib) is the…
-
Biotricity Invites Physicians to Join Shared Revenue Opportunity, Provides Clinics with Remote Devices for Improved Monitoring and Diagnosis
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Ranked as one of the fastest-growing companies in the healthcare sector, Biotricity Inc. (NASDAQ: BTCY) sets out to leave an imprint on all 50 states with its connected, real-time monitoring medtech device. For the last 19 months, Dr. Waqaas Al-Siddiq, CEO, chairman and founder of Biotricity, has led his company to list on a major exchange and expand into 23 different states across the U.S. The company’s flagship device — the Bioflux — is a wearable that gives doctors and cardiologists the ability to monitor and diagnose…
-
Is Generation Hemp Now A Leader in Pure-Play Hemp Operations for the Industrial Sector?
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. A leader in the “Industrial Evolution,” Generation Hemp, Inc. (OTCQB: GENH) is showing the world just what it means to be a pure-play business — especially when it comes to industrial hemp operations. Generation Hemp focuses solely on the practical and industrial use of hemp and its byproducts, ensuring no part of this “wonder plant” goes to waste. As the hemp industry continues to blossom, Generation Hemp moves ahead to serve and target within the midstream sector, vertically integrating along the supply chain through acquisitions of successful…
-
Groundbreaking Studies to Be Conducted on the Effectiveness of Short and Long-term COVID-19 Therapies Inhibiting the Progression of SARS-CoV-2
Previously Published to Benzinga: The following post was written and/or published as a collaboration between Benzinga’s in-house sponsored content team and a financial partner of Benzinga. Statera Biopharma, Inc. (NASDAQ: STAB) recently announced that it has officially received Institutional Review Board (IRB) approval to conduct a Phase 1 pilot study at Loma Linda University Health to evaluate STAT-205 as a treatment in the mitigation of SARS-CoV-2 progression. STAT-205 is a breakthrough immuno-modulator designed to decrease elevated inflammatory responses that are associated with viral infections and inhibit viral replication in human lung cells. Its efficacy was successfully demonstrated during preclinical in vitro studies, where STAT-205 was able to inhibit the replication of…
You May Also Like
Statera BioPharma: The Ticker Formerly Known as CBLI
Generation Hemp’s Green Policy is Inspired by a Cause, Executives Move From Oil and Gas to Industrial Green
What is ImQuest, and How is Statera Biopharma using it to Develop New Immune Therapies for Cancer, Infectious Disease and Autoimmune Disorders?
